Ensign Peak Advisors’s Royalty Pharma RPRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $26.7M | Buy |
741,036
+461,147
| +165% | +$16.6M | 0.05% | 271 |
|
|
2025
Q1 | $8.71M | Buy |
279,889
+69,918
| +33% | +$2.18M | 0.02% | 498 |
|
|
2024
Q4 | $5.36M | Sell |
209,971
-1,208
| -0.6% | -$30.8K | 0.01% | 630 |
|
|
2024
Q3 | $5.97M | Buy |
211,179
+39,483
| +23% | +$1.12M | 0.01% | 574 |
|
|
2024
Q2 | $4.53M | Sell |
171,696
-5,771
| -3% | -$152K | 0.01% | 651 |
|
|
2024
Q1 | $5.39M | Buy |
177,467
+47,642
| +37% | +$1.45M | 0.01% | 617 |
|
|
2023
Q4 | $3.65M | Buy |
129,825
+7,004
| +6% | +$197K | 0.01% | 708 |
|
|
2023
Q3 | $3.33M | Sell |
122,821
-719,719
| -85% | -$19.5M | 0.01% | 676 |
|
|
2023
Q2 | $25.9M | Sell |
842,540
-28,274
| -3% | -$869K | 0.05% | 257 |
|
|
2023
Q1 | $31.4M | Sell |
870,814
-273,327
| -24% | -$9.85M | 0.07% | 230 |
|
|
2022
Q4 | $45.2M | Buy |
1,144,141
+466,225
| +69% | +$18.4M | 0.1% | 179 |
|
|
2022
Q3 | $27.2M | Buy |
677,916
+579,802
| +591% | +$23.3M | 0.07% | 230 |
|
|
2022
Q2 | $4.12M | Buy |
98,114
+6,729
| +7% | +$283K | 0.01% | 593 |
|
|
2022
Q1 | $3.56M | Buy |
91,385
+40,440
| +79% | +$1.58M | 0.01% | 682 |
|
|
2021
Q4 | $2.03M | Buy |
+50,945
| New | +$2.03M | ﹤0.01% | 946 |
|
|
2021
Q3 | – | Sell |
-2,530
| Closed | -$104K | – | 1874 |
|
|
2021
Q2 | $104K | Sell |
2,530
-29,370
| -92% | -$1.21M | ﹤0.01% | 1779 |
|
|
2021
Q1 | $1.39M | Buy |
31,900
+20,344
| +176% | +$887K | ﹤0.01% | 1283 |
|
|
2020
Q4 | $578K | Buy |
11,556
+9,881
| +590% | +$494K | ﹤0.01% | 1573 |
|
|
2020
Q3 | $70K | Buy |
+1,675
| New | +$70K | ﹤0.01% | 1718 |
|